GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Cyclically Adjusted Price-to-FCF

AIM ImmunoTech (LTS:0A4Y) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AIM ImmunoTech Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AIM ImmunoTech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cyclically Adjusted Price-to-FCF Chart

AIM ImmunoTech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted Price-to-FCF falls into.


;
;

AIM ImmunoTech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AIM ImmunoTech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, AIM ImmunoTech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.034/134.9266*134.9266
=-0.034

Current CPI (Mar. 2025) = 134.9266.

AIM ImmunoTech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -11.626 100.684 -15.580
201509 -7.510 100.392 -10.093
201512 -7.228 99.792 -9.773
201603 -2.356 100.470 -3.164
201606 -3.306 101.688 -4.387
201609 -6.171 101.861 -8.174
201612 -3.858 101.863 -5.110
201703 -5.220 102.862 -6.847
201706 -3.721 103.349 -4.858
201709 -2.806 104.136 -3.636
201712 -1.066 104.011 -1.383
201803 -3.102 105.290 -3.975
201806 -2.705 106.317 -3.433
201809 -2.830 106.507 -3.585
201812 -2.206 105.998 -2.808
201903 -1.379 107.251 -1.735
201906 -1.520 108.070 -1.898
201909 -0.986 108.329 -1.228
201912 -0.230 108.420 -0.286
202003 -0.192 108.902 -0.238
202006 -0.049 108.767 -0.061
202009 -0.077 109.815 -0.095
202012 -0.077 109.897 -0.095
202103 -0.075 111.754 -0.091
202106 -0.036 114.631 -0.042
202109 -0.074 115.734 -0.086
202112 -0.123 117.630 -0.141
202203 -0.058 121.301 -0.065
202206 -0.049 125.017 -0.053
202209 -0.104 125.227 -0.112
202212 -0.130 125.222 -0.140
202303 -0.076 127.348 -0.081
202306 -0.045 128.729 -0.047
202309 -0.117 129.860 -0.122
202312 -0.200 129.419 -0.209
202403 -0.098 131.776 -0.100
202406 -0.061 132.554 -0.062
202409 -0.057 133.029 -0.058
202412 -0.064 133.157 -0.065
202503 -0.034 134.927 -0.034

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AIM ImmunoTech  (LTS:0A4Y) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AIM ImmunoTech Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Industry
Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines